MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

Home・Akcijų sąrašas・Biogen Inc

Biogen Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

146.67 2.61

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

142.5

Max

147.35

Pagrindiniai rodikliai
By Trading Economics
Pajamos	394M 635M
Pardavimai	215M 2.6B
P/E Sektoriaus vid.	13.846 36.442
Pelno marža	23.995
Darbuotojai	7,605
EBITDA	457M 1B

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+22.99% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-10-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.3B 21B
Ankstesnė atidarymo kaina	144.06
Ankstesnė uždarymo kaina	146.67

Naujienos nuotaikos

By Acuity

10%

90%

11 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

118.15 / 121.17 Palaikymas ir pasipriešinimas

Biogen Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-20 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

2025-10-20 23:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-20 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

2025-10-20 22:14; UTC

Rinkos pokalbiai

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

2025-10-20 22:00; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

2025-10-20 21:49; UTC

Įsigijimai, susijungimai, perėmimai

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

2025-10-20 20:56; UTC

Įsigijimai, susijungimai, perėmimai

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

2025-10-20 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-10-20 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-10-20 20:38; UTC

Uždarbis

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

2025-10-20 20:38; UTC

Uždarbis

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

2025-10-20 20:38; UTC

Uždarbis

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

2025-10-20 20:36; UTC

Uždarbis

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

2025-10-20 20:36; UTC

Uždarbis

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

2025-10-20 20:36; UTC

Uždarbis

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

2025-10-20 20:36; UTC

Uždarbis

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

2025-10-20 20:16; UTC

Rinkos pokalbiai

Canada Labor-Market Indicators Lean Dovish -- Market Talk

2025-10-20 20:05; UTC

Uždarbis

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

2025-10-20 19:39; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

2025-10-20 19:34; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

2025-10-20 19:32; UTC

Rinkos pokalbiai

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

2025-10-20 19:00; UTC

Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

2025-10-20 18:29; UTC

Rinkos pokalbiai

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

2025-10-20 18:11; UTC

Rinkos pokalbiai

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

2025-10-20 18:04; UTC

Rinkos pokalbiai

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

2025-10-20 17:03; UTC

Rinkos pokalbiai

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

2025-10-20 17:01; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-20 17:01; UTC

Rinkos pokalbiai

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

2025-10-20 16:43; UTC

Rinkos pokalbiai

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

2025-10-20 16:25; UTC

Rinkos pokalbiai

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Akcijų palyginimas

Kainos pokytis

Biogen Inc Prognozė

Kainos tikslas

By TipRanks

22.99% į viršų

12 mėnesių prognozė

Vidutinis 175.88 USD 22.99%

Aukščiausias 224 USD

Žemiausias 118 USD

Remiantis 23 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Biogen Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

23 ratings

Pirkti

Laikyti

Parduoti

Remiantis 23 analitikų, pateikusių Biogen Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

118.15 / 121.17Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

11 / 371 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.